1. Home
  2. KYN vs MYGN Comparison

KYN vs MYGN Comparison

Compare KYN & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kayne Anderson Energy Infrastructure Fund Inc.

KYN

Kayne Anderson Energy Infrastructure Fund Inc.

HOLD

Current Price

$14.07

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.66

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KYN
MYGN
Founded
2004
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
481.6M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
KYN
MYGN
Price
$14.07
$4.66
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$7.64
AVG Volume (30 Days)
375.5K
1.5M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
8.99%
N/A
EPS Growth
N/A
N/A
EPS
0.71
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
N/A
$7.19
Revenue Next Year
N/A
$5.64
P/E Ratio
$20.00
N/A
Revenue Growth
N/A
2.33
52 Week Low
$9.82
$3.76
52 Week High
$14.49
$10.32

Technical Indicators

Market Signals
Indicator
KYN
MYGN
Relative Strength Index (RSI) 59.10 41.35
Support Level $12.10 $3.93
Resistance Level $14.49 $5.63
Average True Range (ATR) 0.25 0.42
MACD -0.04 0.04
Stochastic Oscillator 46.63 21.43

Price Performance

Historical Comparison
KYN
MYGN

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: